Analyst firms · Chardan Capital Markets · FBRX

Chardan Capital Markets FBRX price target and rating history

Forte Biosciences Inc. (FBRX) · Health Care

Chardan Capital Markets rates Forte Biosciences Inc. (FBRX) Buy with a $3.50 price target, as of its latest action on Sep 20, 2021. It has published 3 rating actions on FBRX since September 2021, including 2 upgrades and 1 downgrade.

Current rating
Buy
Price target
$3.50
Median target, all firms
Too few
Actions on FBRX
3

Chardan Capital Markets price target on FBRX

$4$3.75$3.5020222023202420252026
Chardan Capital Markets price target on FBRX, each point a stated target, September 2021 to September 2021.

Every Chardan Capital Markets rating on FBRX

How other firms rate FBRX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
BarclaysOverweight$74Jul 21, 2026
Evercore ISIOutperform$65Nov 25, 2025

Questions about Chardan Capital Markets and FBRX

What is Chardan Capital Markets's price target for FBRX?
Chardan Capital Markets's latest stated price target for Forte Biosciences Inc. (FBRX) is $3.50, from its action on Sep 20, 2021.
What is Chardan Capital Markets's rating on FBRX?
Chardan Capital Markets rates FBRX Buy, a bullish rating, as of Sep 20, 2021.
When did Chardan Capital Markets last change its view on FBRX?
On Sep 20, 2021, Chardan Capital Markets upgrades to Buy from Sell, price target $4 to $3.50.

All Chardan Capital Markets ratingsFBRX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.